Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Correction

This article was originally published in The Gray Sheet

Executive Summary

"The Gray Sheet" incorrectly reported in the June 28, 2010, issue that David Buckles, who has become acting ombudsman in the Center for Devices and Radiological Health, will occupy the spot vacated by Casper Uldriks. Buckles will in fact be filling the spot vacated by longtime ombudsman Les Weinstein (1"The Gray Sheet" April 12, 2010). Uldriks' former position as associate director for clinical research & government affairs within the Office of the Center Director is still vacant

You may also be interested in...



People In Brief

CDRH needs new ombudsman: Les Weinstein served his last day as ombudsman for FDA's device center April 9 and now moves to the same post within FDA's new Center for Tobacco Products. Weinstein was appointed as CDRH's first ombudsman in 2000 to handle complaints from outside the agency and disputes between the center and companies. CDRH has yet to name a replacement (1"The Gray Sheet" March 20, 2000). Weinstein released his final annual report for the device center April 7

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

MT029084

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel